Greenland Mines Ltd (NASDAQ: GRML) announced a series of corporate milestones as it transitions into a focused rare earths and critical minerals company, including plans to spin off its biotechnology division in the fourth quarter of 2026. Nasdaq has formally approved the company's application relating to its March 2026 transaction, resolving prior deficiencies and bringing Greenland Mines into full compliance with listing requirements.
The company also completed its acquisition of the Sarfartoq project on Sept. 1 following approval by the Government of Greenland. An independent S-K 1300 Initial Assessment for the ST1 deposit estimated a high-case pre-tax net present value of approximately $2.05 billion and a pre-tax internal rate of return of 118.6%. Greenland Mines said planned annual neodymium-praseodymium oxide production from ST1 would equal approximately 34% of current NdPr oxide refining outside China based on 2025 consumption levels during each of the project's nine scheduled operating years.
This strategic shift underscores the growing importance of rare earth elements, particularly neodymium and praseodymium, which are critical for permanent magnets used in electric vehicles, wind turbines, and other clean energy technologies. As global demand for these minerals surges, Greenland Mines' focus on developing the Sarfartoq project positions it to become a significant non-Chinese supplier in the NdPr market.
The company is also reshaping its board, with Riad El-Dada and Dr. Shalom Hirschman stepping down and capital markets veteran Jason Hawkins joining as Greenland Mines advances Sarfartoq and its Skaergaard palladium-gold-platinum project. This leadership change aligns with the company's renewed emphasis on its mining division and capital markets strategy.
Greenland Mines Ltd is a Nasdaq-listed company with two operating divisions: (1) Mining, focused on the exploration and development of the Skaergaard Project in southeast Greenland and, subject to closing of the previously announced transaction, the Sarfartoq neodymium-praseodymium (Nd-Pr) rare earths project in southwest Greenland; and (2) Biotech, including Klotho's KLTO-202 primary indication for ALS. The company's strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals and selected midstream processing opportunities, while advancing its broader North Atlantic Critical Metals Corridor vision linking Greenland resources with allied downstream jurisdictions and industrial infrastructure.
The spin-off of the biotech division will allow each entity to focus on its core operations, potentially unlocking shareholder value. For Greenland Mines, this move simplifies its business model and sharpens its identity as a critical minerals developer. For the biotech unit, it provides an independent path to advance its ALS therapy without the constraints of being part of a mining-focused company.
Investors reacted positively to these developments, as the company's compliance with Nasdaq listing requirements and the completion of the Sarfartoq acquisition remove significant overhangs. The robust economic projections for ST1, with a high-case NPV of $2.05 billion and an IRR of 118.6%, highlight the potential value of the project. As the world seeks to diversify its rare earth supply chain away from China, Greenland Mines is positioning itself as a key player in the Western Hemisphere's critical minerals landscape.
For more information on the full press release, visit this link.
